AstraZeneca, Gilead merger doubted by Wall Street analysts | ||
Monday, 8 June 2020 ()
A merger between AstraZeneca and Gilead Sciences Inc is unlikely due to significant political hurdles, Wall Street analysts said on Monday after a Bloomberg report that the British drugmaker last month had contacted its U.S. rival about a deal. |
| ||||||
| ||||||
